RESUMEN
BACKGROUND: This international, randomized, double-blind phase III study (ONO-4538-52/TASUKI-52) evaluated nivolumab with bevacizumab and cytotoxic chemotherapy as first-line treatment for nonsquamous non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Between June 2017 and July 2019, this study enrolled treatment-naïve patients with stage IIIB/IV or recurrent nonsquamous NSCLC without sensitizing EGFR, ALK, or ROS1 alterations. They were randomly assigned in a 1 : 1 ratio to receive nivolumab or placebo in combination with carboplatin, paclitaxel, and bevacizumab every 3 weeks for up to six cycles, followed by nivolumab/placebo with bevacizumab until progressive disease or unacceptable toxicity. The primary endpoint was progression-free survival (PFS) assessed by an independent radiology review committee (IRRC). RESULTS: Overall, 550 patients from Japan, Korea, and Taiwan were randomized; of these patients, 273 and 275 received the nivolumab and placebo combinations, respectively. In the present preplanned interim analysis with a median follow up of 13.7 months, the IRRC-assessed median PFS was significantly longer in the nivolumab arm than in the placebo arm (12.1 versus 8.1 months; hazard ratio 0.56; 96.4% confidence interval 0.43-0.71; P < 0.0001). The PFS benefit was observed across all patients with any programmed death-ligand 1 (PD-L1) expression levels including PD-L1-negative patients. The IRRC-assessed objective response rates were 61.5% and 50.5% in the nivolumab and placebo arms, respectively. The incidence of treatment-related adverse events of grade 3 or 4 was comparable between the two arms; treatment-related adverse events leading to death were observed in five and four patients in the nivolumab and placebo arms, respectively. CONCLUSION: The TASUKI-52 regimen should be considered a viable new treatment strategy for treatment-naïve patients with advanced nonsquamous NSCLC.
Asunto(s)
Carcinoma de Pulmón de Células no Pequeñas , Neoplasias Pulmonares , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Bevacizumab/efectos adversos , Carboplatino/uso terapéutico , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Método Doble Ciego , Humanos , Neoplasias Pulmonares/tratamiento farmacológico , Recurrencia Local de Neoplasia/tratamiento farmacológico , Nivolumab/efectos adversos , Paclitaxel/efectos adversos , Proteínas Tirosina Quinasas , Proteínas Proto-OncogénicasRESUMEN
PURPOSE: Tryptophan metabolites have immunomodulatory functions, suggesting possible roles in cancer immunity. METHODS: Plasma tryptophan metabolites were measured using liquid chromatography/mass spectrometry before immune checkpoint inhibitors (ICIs) in patients with non-small cell lung cancer (NSCLC). RESULTS: The 19 patients with NSCLC had significantly lower levels of tryptophan (p = 0.002) and xanthurenic acid (p = 0.032), and a significantly higher level of 3-hydroxyanthranilic acid (3-HAA) (p = 0.028) compared with the 10 healthy volunteers. The patients achieving objective responses had significantly lower levels of 3-HAA than those who did not (p = 0.045). Receiver operating characteristic analyses determined that the cutoff value of 3-HAA for objective response was 35.4 pmol/mL (sensitivity: 87.5% and specificity: 83.3%). The patients with 3-HAA < 35.4 pmol/mL had significantly longer median progression-free survival (7.0 months) than those without (1.6 months, p = 0.022). CONCLUSIONS: Tryptophan metabolites may have a potential for predicting the efficacy of ICIs. REGISTRATION NUMBER: University Hospital Medical Information Network Clinical Trial Registry 000026140.
Asunto(s)
Ácido 3-Hidroxiantranílico/análisis , Carcinoma de Pulmón de Células no Pequeñas/sangre , Inhibidores de Puntos de Control Inmunológico/uso terapéutico , Neoplasias Pulmonares/sangre , Triptófano/sangre , Xanturenatos/sangre , Adulto , Anciano , Anciano de 80 o más Años , Antígeno B7-H1/sangre , Antígeno B7-H1/metabolismo , Biomarcadores/sangre , Biomarcadores/metabolismo , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Carcinoma de Pulmón de Células no Pequeñas/mortalidad , Femenino , Humanos , Neoplasias Pulmonares/tratamiento farmacológico , Neoplasias Pulmonares/mortalidad , Masculino , Persona de Mediana Edad , Supervivencia sin Progresión , Estudios Prospectivos , Curva ROC , Análisis de Regresión , Sensibilidad y Especificidad , Resultado del Tratamiento , Triptófano/metabolismoRESUMEN
Phosphodiesterase-5 (PDE-5) inhibitors and endothelin receptor antagonists (ERAs) are standard therapies for pulmonary arterial hypertension (PAH). The inter-individual variability of these pharmacokinetics is reported remarkably large, and therapeutic drug monitoring (TDM) can be useful to improve the likelihood of the desired therapeutic and safety outcomes. This study aimed to develop a LC-MS method to determine the concentrations of five PAH drugs (PDE-5 inhibitors: sildenafil and tadalafil, ERAs: bosentan, macitentan, and ambrisentan) from plasma samples using a simple process followed by a single mass spectrometric run, and to validate this approach through pharmacokinetic analyses in patients. A solid extraction method was used for sample preparation of the drugs from human plasma. The total run time for a single injection was within 10 min. The calibration curves for all drugs were linear, and the lower limits of quantitation were 1 (sildenafil), 2 (tadalafil), 5 (ambrisentan), and 10 ng/mL (bosentan, macitentan). The accuracy and precision values suggested that the assay had high accuracy and reliability. To prove the utility of this method, the plasma concentrations of the five PAH drugs were determined after their oral administration to nine PAH patients.
Asunto(s)
Antihipertensivos/análisis , Cromatografía Liquida/métodos , Antagonistas de los Receptores de Endotelina/análisis , Inhibidores de Fosfodiesterasa 5/análisis , Espectrometría de Masas en Tándem/métodos , Administración Oral , Adulto , Anciano , Antihipertensivos/administración & dosificación , Antihipertensivos/sangre , Antagonistas de los Receptores de Endotelina/administración & dosificación , Antagonistas de los Receptores de Endotelina/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Inhibidores de Fosfodiesterasa 5/administración & dosificación , Inhibidores de Fosfodiesterasa 5/sangre , Hipertensión Arterial Pulmonar/tratamiento farmacológico , Reproducibilidad de los ResultadosRESUMEN
BACKGROUND: Respiratory impedance comprises the resistance and reactance of the respiratory system and can provide detailed information on respiratory function. However, details of the relationship between impedance and morphological airway changes in asthma are unknown. OBJECTIVE: We aimed to evaluate the correlation between imaging-based airway changes and respiratory impedance in patients with asthma. METHODS: Respiratory impedance and spirometric data were evaluated in 72 patients with asthma and 29 reference subjects. We measured the intraluminal area (Ai) and wall thickness (WT) of third- to sixth-generation bronchi using three-dimensional computed tomographic analyses, and values were adjusted by body surface area (BSA, Ai/BSA, and WT/the square root (â) of BSA). RESULTS: Asthma patients had significantly increased respiratory impedance, decreased Ai/BSA, and increased WT/âBSA, as was the case in those without airflow limitation as assessed by spirometry. Ai/BSA was inversely correlated with respiratory resistance at 5 Hz (R5) and 20 Hz (R20). R20 had a stronger correlation with Ai/BSA than did R5. Ai/BSA was positively correlated with forced expiratory volume in 1 second/forced vital capacity ratio, percentage predicted forced expiratory volume in 1 second, and percentage predicted mid-expiratory flow. WT/âBSA had no significant correlation with spirometry or respiratory impedance. CONCLUSIONS & CLINICAL RELEVANCE: Respiratory resistance is associated with airway narrowing.
Asunto(s)
Asma/diagnóstico por imagen , Asma/fisiopatología , Imagenología Tridimensional/métodos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Resistencia de las Vías Respiratorias/fisiología , Impedancia Eléctrica , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pruebas de Función Respiratoria , Tomografía Computarizada por Rayos X/métodos , Adulto JovenRESUMEN
OBJECTIVE: Application of immunotherapy using dendritic cells (DCs) is considered an effective treatment strategy against persistent Mycobacterium tuberculosis infection. With the goal of developing improved therapeutic vaccination strategies for patients with tuberculosis (TB), we tested the ability of ex vivo-generated DCs to induce an effective TB antigen-specific type-1 immune response. METHODS: Monocyte-derived DCs from TB patients were induced to mature using a 'standard' cytokine cocktail (interleukin [IL] 1ß, tumour necrosis factor alpha [TNF-α], IL-6 and prostaglandin E2) or a type 1-polarised DC (DC1) cocktail (IL-1ß, TNF-α, interferon [IFN] α, IFN-γ and polyinosinic:polycytidylic acid), and were loaded with the established TB antigen 6-kDa early secretory antigenic target protein (ESAT-6). RESULTS: Although DC1s from TB patients expressed the same levels of multiple co-stimulatory molecules (CD83, CD86, CD80 and CD40) as the standard DCs (sDCs), DC1s secreted substantially higher levels of IL-12p70. Furthermore, when DCs pulsed with or without ESAT-6 were cultured with lymphocytes from the same patients, DC1s induced much higher numbers of ESAT-6-specific IFN-γ-producing T-cells than sDCs, as manifested by their superior induction of natural killer cell activation and antigen-independent suppression of regulatory T-cells. CONCLUSION: TB antigen-loaded DC1s are potent inducers of antigen-specific T-cells, which could be used to develop improved immunotherapies of TB.
Asunto(s)
Células Dendríticas/inmunología , Inmunoterapia/métodos , Mycobacterium tuberculosis/inmunología , Tuberculosis/terapia , Adulto , Anciano , Anciano de 80 o más Años , Antígenos Bacterianos/inmunología , Citocinas/inmunología , Femenino , Humanos , Interleucina-12/inmunología , Activación de Linfocitos/inmunología , Masculino , Persona de Mediana Edad , Monocitos/inmunología , Mycobacterium tuberculosis/aislamiento & purificación , Células T Asesinas Naturales/inmunología , Linfocitos T Reguladores/inmunología , Tuberculosis/inmunología , Adulto JovenRESUMEN
To elucidate whether the pharmacokinetics (PK) and pharmacodynamics (PD) of sildenafil are influenced differently when it is coadministered with bosentan (S+B) or with ambrisentan (S+A), we evaluated the PK and PD profiles of sildenafil before and after 4-5 weeks of S+A or S+B treatment in patients with pulmonary arterial hypertension. The area under the plasma concentration-time curve of sildenafil was significantly higher in S+A treatment than in S+B treatment (165.8 ngâ¢h/mL vs. 396.8 ngâ¢h/mL, P = 0.018) and the oral clearance of sildenafil was significantly lower after S+A treatment than after S+B treatment (120.6 L/h/kg vs. 50.4 L/h/kg, P = 0.018). In the PD study, incremental shuttle walking distance was superior during treatment with S+A than during treatment with S+B (S+B; 280 m vs. S+A; 340 m, P = 0.042). There were no concerns about safety with either combination therapy regime.
Asunto(s)
Hipertensión Pulmonar/tratamiento farmacológico , Fenilpropionatos/farmacocinética , Fenilpropionatos/uso terapéutico , Piridazinas/farmacocinética , Piridazinas/uso terapéutico , Citrato de Sildenafil/farmacocinética , Citrato de Sildenafil/uso terapéutico , Sulfonamidas/farmacocinética , Sulfonamidas/uso terapéutico , Adulto , Bosentán , Quimioterapia Combinada , Ejercicio Físico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Fenilpropionatos/efectos adversos , Fenilpropionatos/farmacología , Piridazinas/efectos adversos , Piridazinas/farmacología , Citrato de Sildenafil/efectos adversos , Citrato de Sildenafil/farmacología , Sulfonamidas/efectos adversos , Sulfonamidas/farmacologíaRESUMEN
BACKGROUND: Pleural fluid is a frequent manifestation in pulmonary diseases, such as lung cancer and infectious diseases, including pulmonary tuberculosis (TB). The enzyme indoleamine 2,3-dioxygenase (IDO) catalyses tryptophan through the kynurenine pathway, and is considered a crucial immunoregulatory molecule mediating immune tolerance. Recent studies have shown IDO activity to be a novel prognostic factor not only in cancer patients but also in those with infectious diseases, including pneumonia and pulmonary TB. However, no studies have measured and determined the clinical significance of IDO activity in pleural fluid. METHODS: We enrolled 92 patients, including 34 with tuberculous pleurisy (TBP), 36 with malignant pleuritis and 15 with parapneumonic effusions. IDO activity was evaluated using liquid chromatography/electrospray ionisation tandem mass spectrometry, and was estimated by calculating kynurenine-to-tryptophan ratio. RESULTS: Pleural fluid from patients with TBP had significantly higher kynurenine concentrations and significantly lower tryptophan concentrations, resulting in significantly higher IDO activity compared with pleural effusion or serum from non-tuberculous pleuritis (all P < 0.001). Pleural tissue from TBP showed enhanced IDO expression in epithelioid granuloma regions by immunohistochemistry. CONCLUSIONS: These results suggest that IDO is strongly involved in the pathogenesis of TBP.
Asunto(s)
Indolamina-Pirrol 2,3,-Dioxigenasa/análisis , Derrame Pleural/enzimología , Tuberculosis Pleural/enzimología , Anciano , Anciano de 80 o más Años , Biomarcadores/análisis , Cromatografía Liquida , Femenino , Humanos , Quinurenina/análisis , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Espectrometría de Masa por Ionización de Electrospray , Espectrometría de Masas en Tándem , Triptófano/análisis , Regulación hacia ArribaRESUMEN
Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A are major factors involved in the metabolism of clinically prescribed drugs. Because the time course after drug treatment discontinuation has received little attention, we aimed to clarify the chronological changes of rifampicin-induced CYP enzyme activities after rifampicin discontinuation. Thirteen volunteers took 450 mg of rifampicin once daily, and the cocktail method, which uses caffeine, losartan, omeprazole, dextromethorphan, and midazolam as CYP-specific probes, was repeatedly used for the evaluation of CYP levels. Concentrations of probes and metabolites were determined by liquid chromatography-tandem mass spectrometry. Seven-day rifampicin administration increased CYP2C19 and CYP3A enzyme activities. The induced CYP2C19 and CYP3A activities remained elevated at 4 days after rifampicin discontinuation and returned to baseline levels 8 days after rifampicin discontinuation. CYP1A2 and CYP2D6 enzyme activities showed no significant changes, and CYP2C9 enzyme activity was increased with rifampicin administration, with a tendency toward statistical significance. Drug interactions can occur even after rifampicin discontinuation.
Asunto(s)
Antibióticos Antituberculosos/farmacología , Sistema Enzimático del Citocromo P-450/metabolismo , Rifampin/farmacología , Adulto , Pueblo Asiatico , Cafeína/farmacocinética , Interacciones Farmacológicas , Femenino , Humanos , Imidazoles/farmacocinética , Losartán/farmacocinética , Masculino , Midazolam/análogos & derivados , Midazolam/farmacocinética , Omeprazol/farmacocinética , Tetrazoles/farmacocinética , Teofilina/farmacocinética , Factores de Tiempo , Privación de TratamientoRESUMEN
SETTING: DosR regulon genes are considered essential for Mycobacterium tuberculosis dormancy, and their products are demonstrated to have immunogenicity in M. tuberculosis-infected individuals, suggesting that DosR regulon-encoded proteins are suitable targets for vaccines to control the reactivation of dormant M. tuberculosis. OBJECTIVE: Prospective analysis of T-cell and antibody responses against DosR regulon-encoded antigens in M. tuberculosis-infected individuals in Japan to identify effective vaccine targets. DESIGN: T-cell responses against 33 DosR regulon-encoded antigens were investigated in 26 consecutive M. tuberculosis-infected individuals--14 with latent tuberculosis infection (LTBI) and 12 with active pulmonary tuberculosis (PTB)--using enzyme-linked immunosorbent spot assay, and antibody responses in 42 consecutive individuals, 14 with LTBI and 28 with PTB. RESULT: Six antigens (Rv0570, Rv1996, Rv2004c, Rv2028c, Rv2029c and Rv3133c) induced stronger T-cell responses in LTBI than in PTB, In contrast, antigen-specific antibody responses to five antigens (Rv0080, Rv1738, Rv2007c, Rv2031c and Rv2032) were found to be stronger in PTB than in LTBI cases. CONCLUSION: T-cell responses to six antigens might contribute to natural protection against dormant M. tuberculosis. These antigens are therefore considered to be potential targets of novel vaccines to control M. tuberculosis reactivation in the Japanese population.
Asunto(s)
Antígenos Bacterianos/inmunología , Tuberculosis Latente/inmunología , Mycobacterium tuberculosis/inmunología , Tuberculosis Pulmonar/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Formación de Anticuerpos/inmunología , Proteínas Bacterianas/genética , Proteínas Bacterianas/inmunología , Proteínas de Unión al ADN , Ensayo de Immunospot Ligado a Enzimas , Femenino , Humanos , Japón , Tuberculosis Latente/genética , Masculino , Persona de Mediana Edad , Mycobacterium tuberculosis/genética , Estudios Prospectivos , Proteínas Quinasas/genética , Proteínas Quinasas/inmunología , Regulón/genética , Regulón/inmunología , Linfocitos T/inmunología , Tuberculosis Pulmonar/genéticaRESUMEN
BACKGROUND: Pulmonary dendritic cells (DCs) are key regulators of immune responses. An increased accumulation of DCs was reported in the lungs of patients with idiopathic interstitial pneumonia (IIP). OBJECTIVE: This study aimed to investigate the number of pulmonary DCs in patients with collagen vascular disease associated interstitial lung diseases (CVD-ILDs). DESIGN: Lung tissue samples obtained from 27 patients with IIP and 39 patients with CVD-ILD were detected using monoclonal antibodies against CD1a, CD1c, CD83, Langerin and DC-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN). RESULTS: No significant differences in the number or distribution of DCs were observed between patients with IIP and CVD-ILDs. When DC marker expression was analyzed according to pathological subgroup, patients with idiopathic usual interstitial pneumonia (UIP) showed increased DC-SIGN staining when compared with CVD-UIP (p < 0.05). CONCLUSION: Both mature and immature DCs accumulate in CVD-ILDs. The number of DCs expressing DC-SIGN in CVD-UIP was decreased compared with that in idiopathic UIP. The variation in accumulated DC-SIGN-positive cells might help to explain the differences in the development and maintenance of lung inflammation between idiopathic UIP and CVD-UIP.
Asunto(s)
Células Dendríticas/inmunología , Fibrosis Pulmonar Idiopática/inmunología , Enfermedades Pulmonares Intersticiales/inmunología , Pulmón/inmunología , Anciano , Anciano de 80 o más Años , Antígenos CD/análisis , Antígenos CD1/análisis , Biomarcadores/análisis , Biopsia , Moléculas de Adhesión Celular/análisis , Femenino , Glicoproteínas/análisis , Humanos , Fibrosis Pulmonar Idiopática/clasificación , Fibrosis Pulmonar Idiopática/patología , Inmunoglobulinas/análisis , Lectinas Tipo C/análisis , Pulmón/patología , Enfermedades Pulmonares Intersticiales/clasificación , Enfermedades Pulmonares Intersticiales/patología , Masculino , Lectinas de Unión a Manosa/análisis , Glicoproteínas de Membrana/análisis , Persona de Mediana Edad , Receptores de Superficie Celular/análisis , Antígeno CD83RESUMEN
Contorted 'phantom' limbs often form when sensory inputs are removed, but the neural mechanisms underlying their formation are poorly understood. We tracked the evolution of an experimental phantom hand during ischaemic anaesthesia of the arm. In the first study subjects showed the perceived posture of their hand and fingers using a model hand. Surprisingly, if the wrist and fingers were held straight before and during anaesthesia, the final phantom hand was bent at the wrist and fingers, but if the wrist and fingers were flexed before and during anaesthesia, the final phantom was extended at wrist and fingers. Hence, no 'default' posture existed for the phantom hand. The final perceived posture may depend on the initial and evolving sensory input during the block rather than the final sensory input (which should not differ for the two postures). In the second study subjects selected templates to indicate the perceived size of their hand. Perceived hand size increased by 34 ± 4% (mean ± 95% CI) during the block. Sensory changes were monitored. In all subjects, impairment of large-fibre cutaneous sensation began distally with von Frey thresholds increasing before cold detection thresholds (Aδ fibres) increased. Some C fibres subserving heat pain still conducted at the end of cuff inflation. These data suggest that changes in both perceived hand size and perceived position of the finger joints develop early when large-fibre cutaneous sensation is beginning to degrade. Hence it is unlikely that block of small-fibre afferents is critical for phantom formation in an ischaemic block.
Asunto(s)
Mano , Percepción , Miembro Fantasma/psicología , Adulto , Anestesia , Brazo , Femenino , Dedos , Mano/anatomía & histología , Mano/fisiología , Humanos , Isquemia , Masculino , Persona de Mediana Edad , Percepción/fisiología , Miembro Fantasma/fisiopatología , Muñeca , Adulto JovenRESUMEN
S-1 is an oral fluorouracil anticancer drug that contains the 5-FU prodrug tegafur. Tegafur has been shown to be converted enzymatically to 5-FU to exert its antitumor effect, and this conversion is principally catalyzed by CYP2A6. Forty-six non-small-cell lung cancer patients were enrolled. The frequencies of the CYP2A6*4C, CYP2A6*7, and CYP2A6*9 alleles were 17.4, 19.6, and 15.2%, respectively. In the S-1 pharmacokinetic analysis, the area under the concentration-time curve from 0 to 10 h (AUC(0-10)) ratios of 5-FU/tegafur showed large interindividual variabilities, ranging from 5.14 to 112.6. The AUC(0-10) for tegafur was 1.5-fold higher in patients with the CYP2A6*4C allele than in patients without the CYP2A6*4C allele P < 0.05). Furthermore, patients with the CYP2A6*4C allele had a significantly lower maximum plasma concentration (102.6 +/- 32.9 ng/ml) for 5-FU than patients without the CYP2A6*4C allele (157.0 +/- 65.5 ng/ml, P < 0.05). Genotyping of CYP2A6 polymorphisms may provide vital information for effective cancer therapy using S-1.
Asunto(s)
Antimetabolitos Antineoplásicos/farmacocinética , Hidrocarburo de Aril Hidroxilasas/genética , Pueblo Asiatico/genética , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Fluorouracilo/farmacocinética , Neoplasias Pulmonares/tratamiento farmacológico , Oxigenasas de Función Mixta/genética , Ácido Oxónico/farmacocinética , Tegafur/farmacocinética , Adulto , Anciano , Alelos , Antimetabolitos Antineoplásicos/sangre , Antimetabolitos Antineoplásicos/uso terapéutico , Área Bajo la Curva , Carcinoma de Pulmón de Células no Pequeñas/etiología , Carcinoma de Pulmón de Células no Pequeñas/genética , Citocromo P-450 CYP2A6 , Combinación de Medicamentos , Femenino , Fluorouracilo/sangre , Genotipo , Humanos , Neoplasias Pulmonares/etiología , Neoplasias Pulmonares/genética , Masculino , Persona de Mediana Edad , Ácido Oxónico/uso terapéutico , Fumar/efectos adversos , Fumar/genética , Fumar/metabolismo , Tegafur/uso terapéuticoAsunto(s)
Agonistas Adrenérgicos beta/administración & dosificación , Albuterol/análogos & derivados , Androstadienos/administración & dosificación , Antiinflamatorios/administración & dosificación , Antineoplásicos/efectos adversos , Enfermedades Bronquiales/inducido químicamente , Enfermedades Bronquiales/tratamiento farmacológico , Broncodilatadores/administración & dosificación , Hemangioendotelioma/tratamiento farmacológico , Interleucina-2/efectos adversos , Neoplasias Cutáneas/tratamiento farmacológico , Administración por Inhalación , Anciano , Anciano de 80 o más Años , Albuterol/administración & dosificación , Antineoplásicos/administración & dosificación , Constricción Patológica/inducido químicamente , Constricción Patológica/tratamiento farmacológico , Preparaciones de Acción Retardada , Esquema de Medicación , Femenino , Fluticasona , Volumen Espiratorio Forzado/efectos de los fármacos , Humanos , Infusiones Intravenosas , Inyecciones Intralesiones , Interleucina-2/administración & dosificación , Masculino , Persona de Mediana Edad , Premedicación , Xinafoato de SalmeterolRESUMEN
The aim of the present study was to clarify the clinical characteristics and prognosis of patients with interstitial lung disease (ILD) associated with amyopathic dermatomyositis (ILD-ADM). The study consisted of 14 consecutive patients with ILD-ADM. Patients were classified into two categories, acute/subacute and chronic forms, according to the clinical presentation of ILD. The clinical features, responsiveness to therapy, and prognosis between the two forms were compared. Nine ILD-ADM patients were categorised as the acute/subacute form, and five as the chronic form. Arterial oxygen tension was significantly lower in the acute/subacute ILD than chronic ILD patients. On high-resolution computed tomography, ground-glass opacities were frequently found in the two forms, but consolidation was more common in acute/subacute ILD than chronic ILD. Bronchoalveolar lavage analysis showed higher numbers of total cells and lymphocytes in acute/subacute ILD than chronic ILD. Histologically, the most common finding was nonspecific interstitial pneumonia in the two forms, while diffuse alveolar damage was only found in acute/subacute ILD. Acute/subacute ILD was generally resistant to therapy, while chronic ILD responded well. Notably, the mortality of acute/subacute ILD was much higher than that of chronic ILD (67 versus 0%, respectively). In conclusion, interstitial lung disease associated with amyopathic dermatomyositis includes two different forms, the acute/subacute and chronic forms, with distinct prognoses.
Asunto(s)
Dermatomiositis/complicaciones , Enfermedades Pulmonares Intersticiales/complicaciones , Enfermedad Aguda , Anciano , Enfermedad Crónica , Progresión de la Enfermedad , Femenino , Humanos , Enfermedades Pulmonares Intersticiales/clasificación , Enfermedades Pulmonares Intersticiales/diagnóstico por imagen , Masculino , Persona de Mediana Edad , Pronóstico , RadiografíaRESUMEN
The author examined the lateralization of transfer of visuomotor information between the right and left hands during unimanual finger-tapping sequences with visual feedback. The finger-tapping task consisted of a target peak force of 2 N and a target intertap interval of 500 ms. Twenty right-handed and 10 left-handed participants performed the motor task, with 3 transfer trials following 3 practice trials. The author observed positive transfers from the left to the right hand for right-handers but the opposite direction of positive transfers for left-handers. However, left-handers showed a less variable peak force than right-handers did. The author discusses left-handers' interhemispheric information processing.
Asunto(s)
Lateralidad Funcional/fisiología , Movimiento/fisiología , Transferencia de Experiencia en Psicología , Percepción Visual/fisiología , Adolescente , Adulto , Dedos/fisiología , Humanos , Masculino , Práctica PsicológicaRESUMEN
BACKGROUND: Eosinophilic tracheobronchitis with cough hypersensitivity, abbreviated as atopic cough, is an important cause of chronic cough. The reason for the absence of airway hyper-responsiveness is unknown, differing from asthma, a Th2 cytokine-mediated disorder. OBJECTIVE: To compare the type 1 helper T cell (Th1)/Th2 balance in the peripheral blood from subjects with atopic cough and atopic asthma, we assessed the intracellular cytokine production at the single-cell level. METHODS: Thirty-six subjects (10 patients with atopic cough, 18 with atopic asthma, and eight control subjects) were included. Intracellular IL-4 and IFN-gamma were detected in CD4+ T cells by flow cytometry. RESULTS: A significantly lower ratio of IFN-gamma-/IL-4-producing CD4+ T cells after phorbol 12-myristate acetate/ionomycin stimulation was found in patients with atopic cough and atopic asthma compared with normal subjects. In comparison between atopic patients, the ratio of IFN-gamma-/IL-4-producing cells was significantly higher in atopic cough than in atopic asthma. However, the proportion of IL-4-producing CD4+ T cells was significantly higher in patients with atopic asthma than in normal control subjects and no significant difference was detected between patients with atopic cough and normal subjects. No significant difference in the proportion of IFN-gamma-producing cells was found between the subjects. Overall, the total IgE levels were positively correlated to the IL-4-producing cells and inversely correlated to the ratio of IFN-gamma-/IL-4-producing cells. CONCLUSION: These results show the lower degree of Th2 cytokine predominance in atopic cough compared with atopic asthma and suggest the relation between the Th1/Th2 balance and atopic status.
Asunto(s)
Asma/inmunología , Tos/inmunología , Hipersensibilidad/inmunología , Células TH1/patología , Células Th2/patología , Adulto , Anciano , Estudios de Casos y Controles , Femenino , Humanos , Inmunoglobulina E/sangre , Interferón gamma/inmunología , Interleucina-4/inmunología , Masculino , Persona de Mediana Edad , Estadísticas no ParamétricasRESUMEN
To examine the relation between timing and force control during finger taping sequences by both pianists and nonpianists, participants tapped a force plate connected to strain gauges. A series of finger tapping tasks consisted of 16 combinations of pace (intertap interval: 180, 200, 400, or 800 ms) and peak force (50, 100, 200, or 400 g). Analysis showed that, although movement timing was independent of force control under low or medium pace conditions, there were strong interactions between the 2 parameters under high pace conditions. The results indicate that participants adapted the movement by switching from separately controlling these parameters in the slow and moderate movement to coupling them in the fast movement. While variations in the intertap interval affected force production by nonpianists, they had little effect for pianists. The ratios of time-to-peak force to press duration increased linearly in pianists but varied irregularly in nonpianists, as the required force decreased. Thus, pianists regulate peak force by timing control of peak force to press duration, suggesting that training affects the relationship between the 2 parameters.
Asunto(s)
Actividad Motora , Destreza Motora , Música , Soporte de Peso , Adulto , Femenino , Humanos , Masculino , Práctica Psicológica , Desempeño Psicomotor , Tiempo de Reacción , Valores de ReferenciaRESUMEN
A 59-year-old man was admitted to our hospital because of dyspnea. Chest radiography showed infiltration and consolidation in both lung fields. He was clinically diagnosed as having idiopathic interstitial pneumonia (IIP), and histological examination of a thoracoscopic lung biopsy specimen showed nonspecific interstitial pneumonia (NSIP) group 1. Corticosteroid therapy had previously been effective, but about 1 year later the disease recurred. The patient's clinical condition was very similar to the first episode, and is improving in response to the same treatment again. Although it is generally accepted that patients with IIP diagnosed histologically as NSIP have a good prognosis, it should be remembered that recurrence is possible, even in patients with group 1.
Asunto(s)
Enfermedades Pulmonares Intersticiales/patología , Humanos , Enfermedades Pulmonares Intersticiales/clasificación , Enfermedades Pulmonares Intersticiales/diagnóstico , Masculino , Persona de Mediana Edad , RecurrenciaRESUMEN
This study was designed to examine effects of somatosensory feedback on variations of intertap interval and muscle force in finger-tapping sequences over 10 minutes. Although intertap intervals were decreased on the massed task as the time passed, the intervals were constant in the distributed task. In finger-tapping for a long time, impulses perhaps circulate within the loop circuits between the cerebral motor cortex and the peripheral nerve and subsequently increase further the excitability of the circuits. This increase in the excitability within the circuits may shorten the interval and increase variation of the interval. On the other hand, although peak force increased up to the 5-min. mark on the massed task, the force decreased after the 6-min. mark. This increase of force also may be produced by increasing activation of the corticoperipheral loop circuits. Although the decrease of force was perhaps produced by the fatigue of finger muscles for tapping during a few minutes, fatigue appeared more clearly in muscle force than in timing control. However, the force and the variation were constant in the distributed task.